Treatment of Chemotherapy-induced Nausea and Vomiting

• Status: Completed
• Trial end date: 2012-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Delayed nausea is a common problem after high dose chemotherapy for bone marrow transplantation. This study wants to compare standard prophylactic anti-emetic therapy with the same treatment plus the drug aprepitant (Emend). The hypothesis is that addition of Emend will reduce nausea and vomiting.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Uppsala University Hospital
• Treatments: Aprepitant; Fosaprepitant

Criteria

Inclusion Criteria:

• Age ≥18 years

• Able to communicate in Swedish

• Diagnosis of lymphoproliferative disease

• Scheduled for myeloablative therapy and autologous stem cell transplantation

• Written informed consent

• Able to swallow oral medications

Exclusion Criteria:

• Nausea at baseline (immediately before start of chemotherapy)

• Gastrointestinal obstruction or active peptic ulcer

• Current illness requiring chronic systemic steroids or requirement for chronic use of antiemetic agent(s)

• Hypersensitivity to any component of the study regimen

• Pregnancy or nursing

• Unrelenting hiccups

• Radiation therapy to pelvis or abdomen within 1 week before or after study day 1

• Psychiatric illness or multi-system organ failure

• Hepatic insufficiency with ASAT, ALAT three times over reference value

• Renal insufficiency with creatinin value three times over reference value.